Pfizer Inc. (PFE) reported a 76 percent year-over-year operational adjusted earnings per share growth in its first quarter. Also, the company recorded 82% operational revenue growth overall and 2% operational growth excluding Comirnaty and Paxlovid. The company said its revenue growth was primarily driven by Comirnaty, Paxlovid, Prevnar family in U.S., Eliquis, Vyndaqel and Oncology Biosimilars in U.S.
First quarter adjusted EPS increased to $1.62 from $0.95, prior year. On average, 15 analysts polled by Thomson Reuters expected the company to report profit per share of $1.47, for the quarter. Analysts' estimates typically exclude special items.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com